DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.

[1]  M. Jadoul,et al.  Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  N. Lazar,et al.  The ASA Statement on p-Values: Context, Process, and Purpose , 2016 .

[3]  A. Khwaja,et al.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Robert A Wolfe,et al.  On a preference‐based instrumental variable approach in reducing unmeasured confounding‐by‐indication , 2015, Statistics in medicine.

[5]  Getachew Tegegne,et al.  Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  Robest Yong,et al.  "VisionTouch Phone" for the Blind. , 2013, The Malaysian journal of medical sciences : MJMS.

[7]  H. Arima,et al.  Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  B. Altun,et al.  Major Barriers against Renin–Angiotensin–Aldosterone System Blocker Use in Chronic Kidney Disease Stages 3–5 in Clinical Practice: A Safety Concern? , 2012, Renal failure.

[9]  L. McMahon,et al.  The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  D. Marcelli,et al.  Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. , 2010, Journal of the American College of Cardiology.

[11]  M. Tonelli,et al.  Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[12]  Frits R Rosendaal,et al.  Cardiovascular and noncardiovascular mortality among patients starting dialysis. , 2009, JAMA.

[13]  J. Bragg-Gresham,et al.  Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  M. Valsecchi,et al.  Sudden death and associated factors in a historical cohort of chronic haemodialysis patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[16]  D. Grobbee,et al.  Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials , 2009, The Lancet.

[17]  Tsutomu Inoue,et al.  Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  W. Winkelmayer,et al.  Associations of kidney function with cardiovascular medication use after myocardial infarction. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[19]  M. Onuigbo,et al.  Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis. , 2008, QJM : monthly journal of the Association of Physicians.

[20]  S. Balamuthusamy,et al.  Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. , 2008, American heart journal.

[21]  S. Greenland,et al.  Serum and dialysate potassium concentrations and survival in hemodialysis patients. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[22]  D. Kent,et al.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[23]  J. Bouchard,et al.  Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[24]  F. Zannad,et al.  Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. , 2006, Kidney international.

[25]  Y. Dohi,et al.  Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  M. Etminan,et al.  Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. , 2006, Journal of the American College of Cardiology.

[27]  L. Smeeth,et al.  Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis , 2005, The Lancet.

[28]  S. Yusuf,et al.  Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .

[29]  K. D. Workgroup.  K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  M. Kutner,et al.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): design, data elements, and methodology. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[32]  A. Hofman,et al.  Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). , 2004, Journal of the American College of Cardiology.

[33]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[34]  R. Wolfe,et al.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2003, Journal of the American Society of Nephrology : JASN.

[35]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[36]  H. Krumholz,et al.  Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. , 2003, Journal of the American College of Cardiology.

[37]  P. Golino,et al.  Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. , 2003, Journal of the American College of Cardiology.

[38]  C. Reid,et al.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly. , 2003, The New England journal of medicine.

[39]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[40]  David A. Calhoun,et al.  Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.

[41]  C. van Walraven,et al.  Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. , 2002, The American journal of medicine.

[42]  G. Bakris,et al.  ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. , 2000, Kidney international.

[43]  M. Perazella,et al.  Hyperkalemia in the elderly , 1997, Journal of General Internal Medicine.

[44]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[45]  A. E. El Nahas,et al.  The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  Trevillore E. Raghunathan,et al.  IVEware: Imputation and Variance Estimation Software User Guide , 2002 .

[47]  R. Wolfe,et al.  The Dialysis Outcomes and Practice Patterns Study (DOPPS): An international hemodialysis study , 2000 .